Evaluation of the Safety and Effectiveness of Switching From Humira® to Imraldi® in Flanders

PHASE4CompletedINTERVENTIONAL

Enrollment

130

Participants

Timeline

Start Date

August 19, 2019

Primary Completion Date

January 29, 2021

Study Completion Date

January 29, 2021

Conditions

Inflammatory Bowel Diseases

Interventions

DRUG

single arm

switch from originator (Humira) to biosimilar (Imraldi)

Trial Locations (2)

AZ Maria Middelares Gent, Ghent

OLV Aalst, Aalst

All Listed Sponsors

lead

Pieter Dewint, MD PhD

OTHER

NCT04045782 - Evaluation of the Safety and Effectiveness of Switching From Humira® to Imraldi® in Flanders | Biotech Hunter | Biotech Hunter